Biomarker Testing in NSCLC

Source: Testing Before Treating: Molecular Determinants of Optimal Therapy for NSCLC
Download Slideset
Review this slideset on current recommendations for evidence-based biomarker testing to guide treatment decision-making for patients with NSCLC from Matthew Gubens, MD, MS, and Craig Mackinnon, MD, PhD.
Matthew Gubens, MD, MS
Craig Mackinnon, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 7.86 MB
Released: July 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC in partnership with the Association for Molecular Pathology
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Genentech
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lilly
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings